Table 2.
Variables associated with overall survival.
| Variable | Univariate | Multivariate | ||
|---|---|---|---|---|
| p Value | HR (95% CI) | p Value | HR (95% CI) | |
| Group | 0.054 | 0.722 | - | - |
| (SBRT vs. CCRT) | (0.518–1.006) | |||
| Age | 0.033 | 1.019 | - | - |
| (1.001–1.036) | ||||
| Gender | 0.739 | 0.946 | - | - |
| (M vs. F) | (0.681–1.313) | |||
| ECOG PS | 0.038 | 2.146 | - | - |
| (0–1 vs. 2) | (1.044–4.411) | |||
| Pre-RT CA19-9 | 0.074 | 1.400 | 0.056 | 1.452 |
| (≤37 vs. >37) | (0.968–2.024) | (0.990–2.128) | ||
| Tumor location | 0.165 | 0.791 | - | - |
| (Head vs. Body/tail) | (0.568–1.102) | |||
| Tumor size | 0.005 | 1.625 | 0.032 | 1.463 |
| (≤40 vs. >40) | (1.162–2.273) | (1.034–2.070) | ||
| Clinical N stage | 0.524 | 1.125 | - | - |
| (N0 vs. N+) | (0.783–1.618) | |||
| Abutting the stomach/duodenum | 0.052 | 1.438 | - | - |
| (No vs. Yes) | (0.997–2.074) | |||
| Induction CTx | 0.365 | 0.858 | - | - |
| (No vs. Yes) | (0.617–1.195) | |||
| Induction CTx duration | 0.017 | 0.540 | 0.034 | 0.572 |
| (≤6 months vs. >6 months | (0.325–0.896) | (0.341–0.958) | ||
| RT dose (EQD2) | 0.202 | 0.986 | - | - |
| (0.966–1.007) | - | - | ||
| Resection | 0.022 | 0.410 | 0.004 | 0.230 |
| (No vs. Yes) | (0.191–0.880) | (0.097–0.543) | ||
Abbreviations: SBRT, stereotactic body radiotherapy; CCRT, concurrent chemoradiotherapy; ECOG PS, Eastern Cooperative Oncology Group performance status; RT, radiotherapy; CA19-9, carbohydrate antigen 19-9; CTx, chemotherapy; EQD2, equivalent dose in 2 Gy per fraction.